Oxford BioTherapeutics announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to an oncology target from an ongoing discovery collaboration.
The target was discovered using Oxford BioTherapeutics' proprietary OGAP system, which incorporates one of the world's largest proprietary proteomic databases, integrating clinical, experimental and expression data.
|Searching for more deal information? Current Partnering offers the following options:
This represents the first option exercised under the companies' oncology target discovery and validation collaboration established in 2013.
Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target.
Oxford BioTherapeutics will receive development and regulatory milestone payments, and royalties on any future product sales.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
View: Top biotech companies